Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Roswell Park Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
Ipsen
Northwestern University
Ohio State University Comprehensive Cancer Center
BeiGene
Shattuck Labs, Inc.
Ipsen
Acerta Pharma BV
Amgen
MorphoSys AG
Hackensack Meridian Health
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Amgen
Stanford University
Nordic Nanovector
Ipsen
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
GlaxoSmithKline
Cancer Research UK
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Fred Hutchinson Cancer Center
University of Washington
Pfizer
GlaxoSmithKline
Takeda
Dartmouth-Hitchcock Medical Center
Massachusetts General Hospital
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center